Abstract
In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 837-855 |
| Number of pages | 19 |
| Journal | Gastroenterology Clinics of North America |
| Volume | 35 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2006 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases. / Reddy, Jagadeshwar G.; Loftus, Jr, Edward Vincent.
In: Gastroenterology Clinics of North America, Vol. 35, No. 4, 12.2006, p. 837-855.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases
AU - Reddy, Jagadeshwar G.
AU - Loftus, Jr, Edward Vincent
PY - 2006/12
Y1 - 2006/12
N2 - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.
AB - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.
UR - http://www.scopus.com/inward/record.url?scp=33751334334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751334334&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2006.09.008
DO - 10.1016/j.gtc.2006.09.008
M3 - Review article
C2 - 17129816
AN - SCOPUS:33751334334
VL - 35
SP - 837
EP - 855
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
SN - 0889-8553
IS - 4
ER -